美國據報已通知航太企業 準重啓對中國商飛交付飛機引擎及零部件
《路透》引述消息報道,美國政府已通知通用航太(GE Aerospace)(GE.US)重啓對中國商飛公司(COMAC)的飛機引擎交付。
有關出口許可涉及中國商飛C919窄體客機的LEAP-1C引擎及C909區域客機的CF34引擎。LEAP-1C引擎由通用航太及法國賽峯(Safran)聯合生產。
報道亦引述消息指,另外至少一間航太企業對華出口許可的暫停亦已獲解除,但消息拒絕指出涉及哪間公司。霍尼韋爾(HON.US)航太部門向中國商飛C919供應部件,包括輔助動力系統、車輪和剎車、飛行控制套件以及導航套件。RTX(RTX.US)旗下Collins Aerospace亦有爲中國商飛提供零部件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.